Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.71 |
| ▸ | GAA | P10253 | 2/20 | 0.71 |
| ▸ | TP53 | P04637 | 3/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.65 |
| ▸ | P4HB | P07237 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9965576 | 0.89 | P4HB (0.81) | MAPTGAATP53KDM4EALDH1A1 | |
| SCHEMBL13835966 | 0.88 | MAPT (0.79) | MAPTGAATP53KDM4ELMNA | |
| SCHEMBL15700803 | 0.85 | MAPT (0.66) | MAPTGAATP53KDM4EMAPK1 | |
| SCHEMBL17799220 | 0.85 | MAPT (0.63) | MAPTGAATP53KDM4EMAPK1 | |
| SCHEMBL2153010 | 0.84 | P4HB (0.82) | MAPTGAATP53KDM4ELMNA | |
| SCHEMBL15783130 | 0.83 | MAPT (0.81) | MAPTGAATP53KDM4EMAPK1 | |
| SCHEMBL2153663 | 0.83 | MAPT (1.00) | MAPTGAATP53KDM4EALDH1A1 | |
| SCHEMBL9965702 | 0.82 | MAPT (0.73) | MAPTGAATP53KDM4EMAPK1 | |
| SCHEMBL22750970 | 0.81 | MAPT (0.82) | MAPTGAATP53KDM4EALDH1A1 | |
| SCHEMBL9965629 | 0.81 | P4HB (0.82) | MAPTGAATP53KDM4EMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160160205-A1 | PARKIN LIGASE ACTIVATION METHODS AND COMPOSITIONS | An2H Discovery Limited (IE) | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160160205-A1 | PARKIN LIGASE ACTIVATION METHODS AND COMPOSITIONS | PINK1, XIAP, STUB1 | MAPT 1156/4885GAA 198/4885TP53 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.